Business Wire9d
Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced presentation of preclinical data supporting the advancement of ...
AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
Morgan Stanley says REDEFINE-2 misses opportunity to differentiate in diabetes
Morgan Stanley notes Novo Nordisk (NVO) disclosed headline data for CagriSema in REDEFINE-2, with a weight loss and safety ...
Novo Nordisk under pressure as obesity drug disappoints in diabetes trial
Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.
BioSpace12d
Obesity Late-Comer AbbVie Inks Up to $2.2B Amylin Deal With Gubra
AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...
Yahoo Finance13d
Obesity drug outlook: Hopes for stronger treatments, adherence remains a hurdle
Novo pioneered it in 2021 when launching Wegovy (semaglutide of GLP-1 class), and Lilly (covered by our US colleague Courtney Breen) followed up at end-2023 with Zepbound (tirzepatide, dual mechanism ...
Prevention1mon
Scientists Explain ‘Ozempic Blindness,’ Link Between Sudden Vision Loss and Weight Loss Drugs
Tirzepatide is in a class of medications called ... As a result, “it is difficult to delineate the exact mechanism,” he says. Dr. Buettner also points out that he’s never seen this in ...
AOL1mon
Scientists Find Link Between Weight Loss Drugs and Blindness
Tirzepatide is in a class of medications called ... As a result, “it is difficult to delineate the exact mechanism,” he says. Dr. Buettner also points out that he’s never seen this in ...